Drug Trial Radar · NCT07034209
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Apr 7, 2023
Primary completion
Apr 18, 2025
Study completion Apr 18, 2025
Sponsor
- Lead sponsor
- TJ Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study adopts an open-label, single-arm, multicenter design to evaluate the efficacy, safety, tolerability, immunogenicity, and PK characteristics of Plonmarlimab administration in patients with rheumatic and immunological disease-associated HLH (MAS), and to explore biomarkers related to the efficacy of Plonmarlimab.
Conditions
- Hemophagocytic Lymphohistiocytoses
Interventions
PlonmarlimabDrug
Subjects receive Plonmarlimab 6 mg/kg or 10 mg/kg, administered intravenously, once weekly for 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate,ORRTime frame: At the end of Week 8
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Beijing Peking Union Medical College Hospital
Beijing, China
Beijing Peking University People's Hospital
Beijing, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Ruijin Hospital Of Shanghai Jiao tong University School of Medicine
Shanghai, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Renji Hospital of Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.